QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications

Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.